Relationship Between Serum Fetuin-A Levels and Carotid Intima-media Thickness in Turkish Patients with Mild to Moderate Psoriasis. A Case-control Study

Belkiz Uyar, Muhittin Akyildiz, Aynur Solak, Berhan Genc, Ali Saklamaz

Sifa University, Faculty of Medicine, Izmir, Turkey

Corresponding author:
Assist. Professor Belkiz Uyar, MD
35240 172/2 Fevzipaşa Bulvari Basmane
Izmir
Turkey
belkisuyar@gmail.com

Received: August 13, 2014
Accepted: July 30, 2015

ABSTRACT
Previous studies have associated severe psoriasis and psoriatic arthritis with an increased risk of atherosclerosis. However, the association between patients with mild-to-moderate plaque-type psoriasis and atherosclerosis has yet to be studied in depth. This study investigates a) possible correlations between carotid intima-media thickness (CIMT) and serum fetuin-A levels in patients with mild-to-moderate psoriasis and b) correlations between psoriasis severity index (PASI) and fetuin-A levels. The latter correlation was recently reported to be important for wound healing and vascular calcification. In this prospective study, a total of 70 patients with mild-to-moderate psoriasis and 66 control participants were included. PASI, CIMT, and serum fetuin-A levels were examined in all patients. Although the difference in fetuin-A values was not statistically significant between patients with mild-to-moderate plaque-type psoriasis and control groups (P=0.401), the CIMT levels in the psoriasis group were significantly higher than the control group (P=0.002). There were no correlations among fetuin-A levels, CIMT, and PASI. This study establishes an association between mild to moderate psoriasis and atherosclerosis. This study also concludes that, similarly to patients with severe psoriasis, CIMT levels are a better indicator of cardiovascular risk than serum fetuin-A levels in patients diagnosed with mild-to-moderate plaque-type psoriasis.

KEY WORDS: cardiovascular disease, fetuin-A, psoriasis, carotid intima-media thickness, psoriasis area and severity index

INTRODUCTION
Psoriasis is a chronic recurrent inflammatory skin disease affecting 2-3% of the world’s population (1). This condition is a systemic immunological disease that is mainly driven by activated T-helper 1 (Th1) and Th17 lymphocytes. Atherosclerosis is also characterized by Th1-related inflammation, both systemically and locally in arterial walls and atherosclerotic plaques (2). It appears that the inflammatory mechanisms resulting in psoriasis and atherosclerosis overlap significantly.

When assessing coronary artery disease and generalized atherosclerosis, carotid artery intima-media thickness (CIMT) detected by high-resolution B-mode ultrasound is a good indicator of an increased risk of subclinical atherosclerosis (3-7). CIMT is determined by the distances between the vascular intima and media composed of endothelium, smooth muscle, and connective tissue (7). The area between the endothelial and smooth muscle layers is also the area of lipid deposition and plaque formation in patients with atherosclerosis (8).
Fetuin-A is a serum glycoprotein that is synthesized mainly by hepatocytes. A consensus has not been reached regarding how fetuin-A affects the cardiovascular system, including any possible contributions to atherosclerosis. Mori et al. hypothesize that fetuin-A contributes to vascular disease in two distinct ways: by increasing insulin resistance and dyslipidemia and by reducing ectopic calcification (9). These authors also report that varied results were obtained from different patients depending on the severity of disease (9). To our knowledge, there is only one report on the status of fetuin-A in patients with psoriasis (10).

Furthermore, there are reports on fetuin-A interacting with transforming growth factor (TGF)-β and epidermal growth factor (EGF), which play an important role in the pathogenesis of psoriasis (9). In this study we explored a) possible associations between fetuin-A and the severity of psoriasis skin lesions and b) correlations between fetuin-A and subclinical atherosclerosis in mild to moderate psoriasis patients (11).

**PATIENTS AND METHODS**

**Patients and controls**

This was a prospective cross-sectional case-controlled study of 70 patients who attended our dermatology clinic and who were diagnosed with mild-to-moderate plaque-type psoriasis between April 2012 and March 2014. A control group of 66 healthy volunteers, matched for age, gender, and body mass index were recruited.

Age, sex, body mass index, blood pressure, and CIMT were measured and recorded for all of the patients and volunteers. Psoriasis area and severity index (PASI) was calculated in patients with psoriasis. The following parameters were assessed in all patients and healthy volunteers at the time of clinical evaluation: complete blood count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF), serum urea, creatinine, uric acid, aspartate aminotransferase (AST), alanine aminotransferase (ALT), serum glucose, total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides (after an overnight fast).

Patients with any of the following criteria that could affect their cardiovascular status were excluded from the study: history of smoking; hypertension (systolic blood pressure >140 mm Hg and/or diastolic blood pressure >90 mm Hg); body mass index >30 kg/m², coronary artery disease, dyslipidemia (total cholesterol and triglyceride levels in fasting plasma >200 mg/dL), diabetes mellitus (fasting glucose levels >110 mg/dL), chronic renal failure, thyroid disease, rheumatic disease, previous systemic treatment of cardiovascular disease, pregnancy, and a PASI ≥12 (12).

The study was approved by the Ethics Committee of the University of Sifa and was conducted according to the ethical principles of the Declaration of Helsinki. All patients provided informed consent before participating.

**Psoriasis areas and severity index score**

The psoriasis areas and severity index (PASI) score was utilized as an objective method to score psoriasis severity, induration, erythema, and scaling on body surfaces of each patient (13). The PASI score was calculated in all patients as described by Fredriksson and Pettersson (14). A PASI score below 7 was defined as mild, between 7 and 12 as moderate, and above 12 as severe disease (12).

**Carotid intima-media thicknesses**

The intima-media thicknesses (IMT) of the common carotid artery (CCA) was obtained using a real-time ultrasound scanner (Siemens, Acuson Antares, Germany) with a 7.5 MHz, 50 mm linear transducer. CIMT measurements were obtained while the patient was lying in the supine position with their neck rotated in the opposite direction of the examining physician. CCA images were obtained to measure IMT using three different-angled views for each vessel. Initially, a transverse scan of the CCA was performed on the longest extension possible, from the base of the neck to the carotid bulb. At least three IMT points were measured in the near and far walls of the most thickened area of each vessel. Lateral wall measurements were also taken when both thickening was evident and accurate images were possible. Subsequently, two longitudinal view scans of the vessel were taken in the postero-lateral (PL) position, with the transducer positioned parallel to the posterior border of the sternocleidomastoid muscle, and in the antero-lateral (AL) position, with the transducer positioned parallel to the anterior border of the sternocleidomastoid muscle. At least three IMT measurements were obtained for each near and far wall of each position. Optimal B-mode settings of gain, depth, focal zone placement, and compression were individually adjusted for each vessel to enhance the arterial wall structures and image quality. IMT was measured manually using electronic calipers, as previously described by Sidhu and Desai (15). The maximum IMT value was selected for each angle. For further data analyses, the maximum
value of either the right or left carotid artery was also measured. An IMT of greater than 1.0 mm was considered to be abnormal (16).

**Biochemical parameters**

For sample preparation, 8 mL of venous blood was collected in serum tubes (Vacuette-Z Serum Sep Clot Activator, Greiner bio-one GmbH, Kremsmünster, Austria) and centrifuged at 2000 g after clotting for 10 min at room temperature. Serum samples were stored at -80°C until time of the assay. Fetuin-A was measured with a human enzyme-linked immunosorbent assay (ELISA) kit (analytical sensitivity: 0.37 ng/mL) (Alfa-2-Heremans Schid Glycoprotein, Uscn Life Science Inc. Wuhan, China).

**Statistical analyses**

The normality of data was analyzed using the Kolmogorov-Smirnov Test. All numerical variables with a normal distribution were expressed as a mean ± standard deviation, while data that were not determined to be normally distributed were expressed as median with interquartile ranges (IR). Continuous variables were compared using Student’s t-test or the Mann-Whitney U test. Correlations among CIMT, PASI, and fetuin-A were determined using Pearson’s partial correlation calculation. \( P \) values of less than 0.05 were considered statistically significant. Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS) version 20 (SPSS, Chicago, IL).

**RESULTS**

The demographics of patients and controls, including age, sex, and body mass index, were similar.
patients with mild-to-moderate plaque-type psoriasis and atherosclerosis had not been fully investigated.

In this study, CIMT levels were found to be significantly higher in patients with mild-to-moderate psoriasis compared to controls (patients with psoriasis: 0.80 (0.36), controls: 0.55 (0.24); \( P = 0.002 \)). However, we did not find any correlation between CIMT and PASI scores. These results seem to support previous reports that there is no correlation between disease activity and CIMT scores (18,20).

Psoriasis is characterized by excessive growth and aberrant differentiation of keratinocytes in skin lesions. Flisiak et al. previously reported that some inflammatory cytokines, including transforming growth factor (TGF) \( \beta \), are involved in the pathogenesis of psoriasis (21,22). Fetuin-A acts as an anti-inflammatory mediator and natural antagonist of TGF-\( \beta \) (9). In addition, TGF-\( \beta \) is important for negative regulation of keratinocyte proliferation. We hypothesized that reduced TGF-\( \beta \) in patients with psoriasis may be associated with increased levels of fetuin-A, and that fetuin-A is higher in patients with psoriasis when compared to healthy volunteers, which may be related to the observed PASI and/or correlation with CIMT.

Epidermal growth factor (EGF) appears to play a crucial role in the pathogenesis of psoriasis (23).

Wang et al. demonstrated that fetuin-A promotes HaCaT migration via signaling pathways that are similar to the pro-migratory pathways provoked by epidermal growth factor (EGF) and transforming growth factor-\( \alpha \) stimulation (11). They demonstrated that a blockade of EGF receptor signaling has a limited effect on fetuin-A-promoted "wound closure" in primary human keratinocytes but significantly inhibits the effect of fetuin-A on HaCaT cells.

In this study, we aimed to investigate the possible associations between a) fetuin-A levels and the severity of plaque-type psoriasis and b) fetuin-A levels and atherosclerosis. However, no correlations between fetuin-A and PASI scores were observed.

Our analysis expands upon a study by Gerdes et al., in which it is hypothesized that the inflammatory status of patients with psoriasis resulted in a decrease in systemic fetuin-A levels. This decrease in fetuin-A may result in an increased risk of vascular calcification and could provide an explanation for how systemic inflammation during psoriasis contributes to the observed cardiovascular comorbidity (10).

### Table 1. Demographics, laboratory findings, carotid intima-media thickness (CIMT) levels, and psoriasis severity index (PASI) scores of 70 patients with mild-to-moderate psoriasis and 66 matched controls*

<table>
<thead>
<tr>
<th>Variable</th>
<th>Patients (n=70)</th>
<th>Controls (n = 66)</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean ± SD or median (IR)</td>
<td>Mean ± SD or median (IR)</td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td>34.0±10.29</td>
<td>32.3±9.25</td>
<td>0.617</td>
</tr>
<tr>
<td>Men/women</td>
<td>36/34</td>
<td>33/33</td>
<td>0.934</td>
</tr>
<tr>
<td>Body mass index, kg/m(^2)</td>
<td>25.45±4.53</td>
<td>25.94±4.89</td>
<td>0.753</td>
</tr>
<tr>
<td>Serum creatinine, mg/dL</td>
<td>0.81±0.30</td>
<td>0.65±0.10</td>
<td>0.077</td>
</tr>
<tr>
<td>Serum urea, mg/dL</td>
<td>27.57±10.36</td>
<td>23.41±5.053</td>
<td>0.191</td>
</tr>
<tr>
<td>Uric acid, mg/dL</td>
<td>4.72±1.26</td>
<td>3.91±1.02</td>
<td>0.051</td>
</tr>
<tr>
<td>CRP level, mg/dL</td>
<td>0.15 (0.24)</td>
<td>0.13 (0.20)</td>
<td>0.874</td>
</tr>
<tr>
<td>ESR, mm/hour</td>
<td>7.00 (9.00)</td>
<td>10.50 (13.00)</td>
<td>0.309</td>
</tr>
<tr>
<td>RF, IU/dL</td>
<td>9.00 (2.00)</td>
<td>8.00 (0.68)</td>
<td>0.210</td>
</tr>
<tr>
<td>AST, U/L</td>
<td>18.97±4.34</td>
<td>17.00±2.89</td>
<td>0.087</td>
</tr>
<tr>
<td>ALT, U/L</td>
<td>22.74±11.67</td>
<td>15.9±6.59</td>
<td>0.018</td>
</tr>
<tr>
<td>Total cholesterol, mg/dL</td>
<td>176.48±38.09</td>
<td>183.66±26.87</td>
<td>0.550</td>
</tr>
<tr>
<td>HDL cholesterol, mg/dL</td>
<td>51.97±16.15</td>
<td>55.03±13.17</td>
<td>0.557</td>
</tr>
<tr>
<td>LDL cholesterol, mg/dL</td>
<td>110.24±33.19</td>
<td>107.81±37.66</td>
<td>0.840</td>
</tr>
<tr>
<td>Triglycerides, mg/dL</td>
<td>128.57±102.33</td>
<td>112.91±75.65</td>
<td>0.579</td>
</tr>
<tr>
<td>Fasting serum glucose, mg/dL</td>
<td>91.00 (15.00)</td>
<td>90.50 (11.25)</td>
<td>0.660</td>
</tr>
<tr>
<td>Serum Fetuin A, ng/mL</td>
<td>4.59±3.42</td>
<td>3.67±2.61</td>
<td>0.401</td>
</tr>
<tr>
<td>CIMT, mm</td>
<td>0.80 (0.36)</td>
<td>0.55 (0.24)</td>
<td>0.002</td>
</tr>
<tr>
<td>PASI</td>
<td>8.32±5.43</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

*Values are the mean ± standard deviation (SD) or median (interquartile range-IR). CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; HDL: high-density lipoprotein; LDL: low-density lipoprotein; CIMT: carotid intima-media thickness; PASI: psoriasis areas and severity index; RF: rheumatoid factor; AST: aspartate aminotransferase; ALT: alanine aminotransferase.
Gerdes \textit{et al.} found low levels of fetuin-A in patients with chronic kidney disease, dialysis patients, and patients with end-stage renal disease with evidence of inflammation (24,25). In hemodialysis patients, low levels of fetuin-A were associated with increased cardiovascular and all-cause mortality (26). These findings are supported by the repeatedly described observation that fetuin-A is a negative acute phase protein that is down-regulated by acute inflammation. In the rat liver, it was shown that tumor necrosis factor alpha (TNF-\alpha) can reduce fetuin-A gene expression, and in humans, this was shown for Interleukin (IL) 6 and IL-1b (27). Gerdes \textit{et al.} found a significant reduction fetuin-A in patients with psoriasis with and without psoriatic arthritis (10).

In our study, the mean serum concentration of fetuin-A was found to be higher in patients with psoriasis (4.59±3.42) as compared with controls (3.67±2.61), however, this difference was not statistically significant (\textit{P}=0.401).

Ix \textit{et al.} reported that among 1,375 community-living individuals without prevalent clinical cardiovascular disease, lower fetuin-A levels are independently associated with greater coronary artery calcification severity but not peripheral arterial disease or CIMT. They report that fetuin-A might initiate calcium deposition in the vasculature but not atherosclerosis directly. Low fetuin-A levels also may cause patients to be predisposed to greater calcium deposition but not necessarily the initiation or progression of atherosclerosis (28).

In our study, the mean serum concentration of fetuin-A was found to be higher in patients with psoriasis (4.59±3.42) as compared with controls (3.67±2.61), however, this difference was not statistically significant (\textit{P}=0.401).

Ix \textit{et al.} reported that among 1,375 community-living individuals without prevalent clinical cardiovascular disease, lower fetuin-A levels are independently associated with greater coronary artery calcification severity but not peripheral arterial disease or CIMT. They report that fetuin-A might initiate calcium deposition in the vasculature but not atherosclerosis directly. Low fetuin-A levels also may cause patients to be predisposed to greater calcium deposition but not necessarily the initiation or progression of atherosclerosis (28).

Our study and several others support this hypothesis (29,30). In our study, serum fetuin-A levels of patients with psoriasis were not significantly reduced as compared with controls. This could be because the CIMT levels of patients were found to be higher than that of controls. We also found that mild-to-moderate plaque-type psoriasis patients did not exhibit as much calcification as patients with severe psoriasis.

Fetuin A has also been reported to impair insulin signaling and adipocyte function. Fetuin A is associated with insulin resistance, diabetes mellitus, and obesity, all of which have been previously associated with psoriasis (9).

In this study, we observed a correlation between serum fetuin-A levels and fasting glucose, as well as between fetuin-A and LDL cholesterol.

A limitation of our study was that only a small number of patients were enrolled. Cross-sectional data from this small cohort does not allow for causality to be established. Future directions may include expanding our study to include more patients. Another limitation is that we did not analyze men and women separately.

CONCLUSION

Most importantly, this study describes an association between mild-to-moderate psoriasis and atherosclerosis, similarly to severe psoriasis. Interestingly, this association was seen in patients without taking other cardiovascular risk factors into consideration.

We recommend that when assessing the cardiovascular disease risk of patients with psoriasis, physicians should measure CIMT rather than the less appropriate serum fetuin-A values, as many other metabolic events influence fetuin-A levels.

Future studies should evaluate the effect of fetuin-A on excessive growth and aberrant differentiation of keratinocytes. In conclusion, the measurement of fetuin-A levels in psoriasis plaques is more appropriate than the measurement of levels of serum fetuin-A.

References: